- Stocks
- Pharma & Healthcare
- Indoco Remedies
Indoco Remedies share price
NSE: INDOCOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Indoco Remedies at a glance
Indoco Remedies (NSE: INDOCO) closed at ₹235.90 on 19 Oct 2026, down 3.38% on the day. With a market capitalisation of ₹2,177 Cr, it ranks 1122nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −10.1% in FY26. Over the past year the share price has fallen 17.9%. Its 52-week range is ₹162.19 (30 Mar 2026) to ₹291.00 (23 Oct 2025); the last close is 18.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹466 Cr (+8.7% year on year) and net profit ₹65 Cr, on a consolidated basis. Promoters held 58.86% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,177 CrRank 1122 on NSE
- Price to book
- 1.62×FY26
- EPS (TTM)
- ₹0.32to Q1 FY27
- ROE
- −10.1%FY26
- ROCE
- 1.2%FY26
- Debt to equity
- 1.1FY26
- Net profit margin
- −5.3%FY26
- Book value / share
- ₹101.76FY26
- 52-week high
- ₹291.0023 Oct 2025
- 52-week low
- ₹162.1930 Mar 2026
- 1-year return
- −17.9%
- RSI (14-day)
- 46
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.38% | +3.7% | −7.0% | −3.7% | −17.9% |
Indoco Remedies quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹433 Cr | ₹411 Cr | ₹384 Cr | ₹429 Cr | ₹485 Cr | ₹434 Cr | ₹456 Cr | ₹466 Cr |
| Revenue YoY | −10.2% | −10.6% | −14.6% | −0.6% | +12.0% | +5.8% | +18.8% | +8.7% |
| Net profit | −₹10 Cr | −₹28 Cr | −₹41 Cr | −₹36 Cr | −₹9 Cr | −₹29 Cr | −₹24 Cr | ₹65 Cr |
| Net profit YoY | −128.4% | −282.5% | −287.7% | −2,097.3% | — | — | — | — |
| Net margin | −2.3% | −6.9% | −10.8% | −8.5% | −1.9% | −6.8% | −5.2% | 14.0% |
| EPS | −₹1.09 | −₹3.08 | −₹4.48 | −₹3.94 | −₹1.00 | −₹3.20 | −₹2.57 | ₹7.09 |
Indoco Remedies financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,242 Cr | ₹1,541 Cr | ₹1,669 Cr | ₹1,817 Cr | ₹1,665 Cr | — |
| Operating profit | ₹132 Cr | ₹237 Cr | ₹193 Cr | ₹124 Cr | −₹75 Cr | — |
| Net profit | ₹93 Cr | ₹155 Cr | ₹142 Cr | ₹97 Cr | −₹78 Cr | — |
| EPS (₹) | ₹10.00 | ₹17.00 | ₹15.00 | ₹11.00 | −₹8.00 | — |
| Cash from operations | ₹82 Cr | ₹174 Cr | ₹179 Cr | ₹157 Cr | ₹95 Cr | — |
| Total debt | ₹97 Cr | ₹96 Cr | ₹144 Cr | ₹352 Cr | ₹533 Cr | ₹516 Cr |
| Shareholders' equity | ₹769 Cr | ₹905 Cr | ₹1,028 Cr | ₹1,110 Cr | ₹1,022 Cr | ₹939 Cr |
Indoco Remedies shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 58.90% | 58.90% | 58.90% | 58.90% | 58.86% | 58.86% |
| Foreign institutions | 1.24% | 1.22% | 1.25% | 1.10% | 0.94% | 1.27% |
| Domestic institutions | 18.75% | 18.96% | 18.16% | 18.15% | 18.15% | 17.68% |
| Non-institutions | 21.02% | 20.83% | 21.60% | 21.77% | 21.90% | 22.04% |
Indoco Remedies vs peers
The listed Pharma & Healthcare companies nearest to Indoco Remedies by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DCALDishman Carbogen Amcis | ₹146.03 | −2.65% | −50.3% | ₹2,290 Cr | 23.5 | — |
| VIMTALABSVimta Labs | ₹505.00 | −3.55% | −29.2% | ₹2,256 Cr | 29 | — |
| MEDIASSISTMedi Assist Healthcare Services | ₹297.65 | −2.89% | −43.8% | ₹2,224 Cr | 24.5 | — |
| INDOCOIndoco Remedies | ₹235.90 | −3.38% | −17.9% | ₹2,177 Cr | — | — |
| SAIPARENTSai Parenterals | ₹482.75 | −0.97% | — | ₹2,133 Cr | 108.2 | — |
| PANACEABIOPanacea Biotec | ₹347.50 | −3.74% | −20.0% | ₹2,128 Cr | — | — |
| SAKARSakar Healthcare | ₹919.80 | −4.29% | +156.2% | ₹2,047 Cr | 67.3 | — |
Ask anything about Indoco Remedies
Pivot answers on the live chart with evidence you can check, and tests strategies against INDOCO's own history. Try: “Why has INDOCO moved over the last three months?” · “Backtest a 50-day moving-average crossover on INDOCO over five years” · “Compare INDOCO with DCAL on margins and valuation”
Frequently asked questions about Indoco Remedies
What is the share price of Indoco Remedies today?
Indoco Remedies (NSE: INDOCO) last closed at ₹235.90 on 19 Oct 2026. Its 52-week high is ₹291.00 and its 52-week low is ₹162.19.
What is the market cap of Indoco Remedies?
Indoco Remedies' market capitalisation is ₹2,177 Cr (₹2,177 Cr) at the 19 Oct 2026 close, ranking 1122nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Indoco Remedies?
Return on equity was −10.1% in FY26 and return on capital employed was 1.2% in FY26 (consolidated figures).
Is Indoco Remedies a debt-free company?
No. Indoco Remedies' debt-to-equity ratio was 1.1 in FY26, with total debt of ₹516 Cr.
What were Indoco Remedies' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Indoco Remedies reported revenue of ₹466 Cr, +8.7% year on year, and net profit of ₹65 Cr.
How has Indoco Remedies stock performed over the last year?
Indoco Remedies' share price has fallen 17.9% over the past year, −3.7% over three months and −7.0% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Indoco Remedies?
As of 30 Jun 2026: promoters 58.86%, foreign institutions 1.27%, domestic institutions 17.68%, non-institutions 22.04%.
Who are Indoco Remedies' competitors?
The listed Pharma & Healthcare companies closest to Indoco Remedies by market cap are Dishman Carbogen Amcis, Vimta Labs, Medi Assist Healthcare Services, Sai Parenterals, Panacea Biotec and Sakar Healthcare.
Is Indoco Remedies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Indoco Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDOCO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with I · all NSE stocks · this page as text